Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy [2]

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1296-1297

  Merimsky, O ^a   Meller, I ^a   Kollender, Y ^a   Inbar, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GEMCITABINE; VINCRISTINE;

ADULT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LETTER; OSTEOSARCOMA; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PAPILLARY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OSTEOSARCOMA; PALLIATIVE CARE; THYROID NEOPLASMS;

EID: 0032127135     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. 1. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Proc Ann Meet Am Soc Clin Oncol 1993, 12(A698).
2. 2. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996, 7, 347-353.
3. 3. FDA: Quality of life matters! News section. Ann Oncol 1995, 6, 854-860.
4. 4. Malawer MM, Link MP, Donaldson SS. Sarcoma of bones. In DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Fifth edition. Philadelphia, Lippincott-Raven, 1997, Chapter 38, 1731-1852.
5. 5. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995, 22, 42-46.
6. 6. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12(8), 1535-1540.